In a report released yesterday, Stephanie Davis from Barclays maintained a Buy rating on Progyny (PGNY – Research Report), with a price target of $48.00. The company’s shares closed yesterday at $40.79.
Davis covers the Healthcare sector, focusing on stocks such as Healthequity, Laboratory, and McKesson. According to TipRanks, Davis has an average return of -6.7% and a 42.86% success rate on recommended stocks.
Progyny has an analyst consensus of Strong Buy, with a price target consensus of $44.73, which is a 9.66% upside from current levels. In a report released on February 26, Leerink Partners also initiated coverage with a Buy rating on the stock with a $49.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $44.95 and a one-year low of $29.44. Currently, Progyny has an average volume of 701.5K.
Based on the recent corporate insider activity of 91 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PGNY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Progyny (PGNY) Company Description:
Progyny, Inc. is a medical device company, which engages in the field of reproductive medicine, translating scientific discoveries related to early embryo development into clinical tools. Its services include egg freezing, IVF treatment, surrogacy, podcast, adoption, and Eeva Test. The company was founded on April 03, 2008 and is headquartered in New York, NY.
Read More on PGNY:
- Progyny, Inc. Announces Fourth Quarter 2023 Results
- Progyny initiated with an Outperform at Leerink
- PGNY Earnings this Week: How Will it Perform?
- Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2023 Results Report
- Vistia Health selects Progyny as fertility, family building benefits provider
